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 Solvents were distilled under anhydrous conditions. All reagents were purchased and 
used without further purification. Glassware was dried prior to use. Compounds were purified 
by dry flash chromatography using silica 60, <0063 mm and water pump vacuum or by flash-
chromatography using silica 60 Å 230–400 mesh as stationary phases. TLC plates (silica gel 60 
F254) were visualized either at a UV lamp or in iodine. Melting points are uncorrected. The 
specific rotation was determined by AUTOPOL III polarimeter. 
 Elemental analysis was performed on the analyzer Carlo Erba 1108. 
 NMR experiments:  The NMR experiments have been performed on a BRUKER FT NMR 
spectrometer AVANCE 400 (Bruker, Karlsruhe, Germany) (400 MHz for 1H and 100.6 MHz for 
13C) with a BVT 3200 variable temperature unit in 5 mm sample tubes using Bruker Standard 
software (TopSpin 3.1). The 1H and 13C chemical shifts were referenced to internal 
tetramethylsilane (TMS); the experimental parameters for 1H are as follows: digital resolution = 
0.23 Hz, SWH (spectral width in Hz) = 8224 Hz, TD (time domain) = 65 K, SI (Fourier transform 
size) = 32 K, 90 pulse-length = 10 µs, PL1 (power level for F1 channel) = 3 dB, ns (number of 
scans) = 1, ds (number of dummy scans) = 0, d1 (relaxation delay) = 1 s and for 13C as follows: 
digital resolution = 0.27 Hz, SWH = 25253 Hz, TD = 65 K, SI = 32 K, 90 pulse-length = 9 µs, PL1 = 2 
dB, ns = 100, ds = 2, d1 = 3 s.  
 HSQC: pulse program = hsqcetgp, digital resolution = 1.97 Hz, SWH = 5342, TD = 4096, SI 
= 1024, 90 pulse-length = 20 µs, PL1 = 3 dB, ns = 4, ds = 16, d1 = 1.5 s. 
 HMBC: pulse program = hmbcgplpndgf, digital resolution = 1.97 Hz, SWH = 6810, TD = 
4096, SI = 2048, 90 pulse-length = 20 µs, PL1 = 3 dB, ns = 24, ds = 16, d1 = 1.5 s.  
 The NMR-grades DMSO-d6, CDCl3, CD3OD, D2O was used for the solutions of 1-7. 
 IR experiments: Infrared spectra were recorded on a Bomem MB 104. Samples were run 
as oils as thin films. The spectrum was taken in the range of 4000-400 cm-1 at room 
temperature. 
 MS experiments: MS spectra were recorded on a Varian 500-MS LC Ion Trap Mass and 
VG Autopsic M spectrometer. 
Synthesis of new analogue of bicyclic 1-azafagomine (1-7) 
Synthesis of (E)-2,4-pentadienol (1) 
 2,4-Pentadienol 1 was obtained by repeating the literature procedure. In details, 250 ml 
of a necked bottom flask with a magnetic stir bar was placed in an ice bath, where 5.09 g of 2,4-
pentadienic acid, which was dissolved in dried THF (77 ml) and 8.9 ml of NEt3 were added. Then 
5 ml of ethylchloroformate was dissolved in 13 ml of THF, placed in dropping funnel, connected 
with 250 ml three-bottom flask and left it to pour drop by drop for 30 min at -5°-0°C. After 30 
min reaction was stopped, precipitate filtrated under vacuum and washed thoroughly with THF 
(3×50ml) (Solution A).  
 A 1-l three-necked round bottom flask was placed in an ice bath (7°C) where 515 ml of 
H2O and 4.804 g of NaBH4 were added and stirred. Solution A was then added dropwise over 30 
min after which the solution was removed from the ice bath and allowed to stir at ambient 
temperature for 3.5 h. Thereafter, the solution was reinserted into an ice-water bath and 20 ml 
of 37% HCl was added dropwise using a dropping funnel under an N2 atmosphere. The mixture 
obtained was extracted with diethyl ether (2 x 100 ml), and the organic layers were combined 
and extracted with 10% NaOH solution (50 ml), followed by extraction with H2O (50 ml) and 
brine (50 ml), then dried over anhydrous MgSO4 and concentrated to dryness under reduced 
pressure to give a colorless liquid in 31.4% yield, b.p. 58-62°C/11 mmHg (15 Pa). Yield 31.4%. 
The spectroscopic data corresponded to literature values [46], νmax (CHCl3)/cm
-1 3616, 3444, 
2873, 2254, 1824, 1731, 1606, 1455, 1377, 1083, 994, 902; δH (400 MHz; CDCl3) 6.25 (2H, m, 
CH2=CH), 5.74 (1H, dt, J=14.7, 5.7, CH=CH2OH), 5.13 (1H, d, J=16.4, CH), 5.01 (1H, d, J=9.6, CH), 
4.07 (2H, m, CH2OH), 3.12 (1H, br s, OH); δC (100 MHz; CDCl3) 136.2 (CH), 132.5 (CH), 131.2 
(CH), 116.9 (CH2), 62.3 (CH2). Anal. Calcd. for C5H8O: C, 71.42; H, 9.52. Found: C, 71.47; H, 9.48. 
 
Synthesis of (S)-Diethyl-3-(hydroxymethyl)pyridazine-1,2(3H,6H)-dicarboxylate (2) 
 Compounds 2 was obtained according to the procedure. In general, in order to obtain 
compound 2, two different solutions (A and B) were prepared.  
 Solution A: a solution of Me2Zn 1.2 M in toluene (991 µl; 1.19 mmol) was added to a 
solution of penta-2,4-dien-1-ol 1 (0.100 g; 1.19 mmol) in dry toluene (6 ml) at 0°C, and stirred for 
5 min.  
 Solution B: a solution of MeMgBr 1.4 M in toluene/THF (849 µL; 1.19 mmol) was added to 
a solution of (S)-BINOL (0.340 g; 1.19 mmol) in dry toluene (6 ml) at 0°C, and stirred for 5 min. 
 Thereafter, solution A was diluted in dry toluene (10 ml), added to solution B, stirred for 
5 min and then refrigerated at -78ºC. To this mixture, a solution of diethyl azodicarboxylate 
(543 µL; 1.19 mmol) in dry toluene (10 ml) was added. The temperature was allowed to rise 
gradually to room temperature and the reaction mixture was stirred for 18h. The reaction was 
quenched with a saturated solution of NaHCO3 (1 ml), filtered through a pad of Celite®, which 
was washed with EtOAc (3 × 20 ml). The filtrates were combined and concentrated under 
reduced pressure giving a yellow oil. The crude oil was purified by “dry-flash” chromatography 
(silica, petroleum ether / diethyl ether). (S)-BINOL was recovered with petroleum ether (1): 
diethyl ether (1) (0.200 g; 69%) and product (-)-2 with diethyl ether (0.225 g; 73%) as a yellow 
oil. *α+D
20 -23.4º (conc. 1.25% in CHCl3). νmax (neat) 3483, 1707 cm
−1. δH (400 MHz, CDCl3) 1.23-
1.30 (12H, m, 4CH3, A+B), 2.58 (1H, br s, OH), 3.35 (1H, dd, J=12.3, 9.5 Hz, H-3’, A), 3.45 (1H, dd, 
J=12.0, 9.8 Hz, H-3’, B), 3.56-3.69 (2H, m, 2H-3’, A+B), 3.77 (1H, dd, J=13.5, 4.3 Hz, H-6, A), 3.91 
(1H, br s, H-6, B), 4.11-4.26 (8H, m, 4CH2, A+B), 4.30 (1H, tdd, J=6.0, 3.9, 2.2 Hz, H-6, B), 4.34-
4.44 (1H, m, H-6, A), 4.72 (2H, br s, H-3, A+B), 5.66-5.88 (4H, m, H-4 + H-5, A+B) ppm. δC (100 
MHz, CDCl3)
 14.3 (CH3, A), 14.4 (CH3, B), 42.2 (C-6, A), 43.6 (C-6, B), 55.9 (C-3, A), 56.9 (C-3, B), 
61.9 (C-3’, A+B), 62.6, 62.7, 62.8, 62.9 (CH2, A+B), 123.4, 124.2, 124,6, 125.2 (C-4 or C-5, A+B), 
154.9, 155.7, 156.2, 156.3 (C=O, A+B) ppm. HRMS (ESI): calcd for C11H18N2NaO5: 281.1108; 
found: 281.1109. Anal. Calcd. for C11H18N2O5: C, 51.16; H, 6.97; N, 10.85. Found: C, 51.21; H, 
6.91; N, 10.81. 
Synthesis (S)-(1,2,3,6-tetrahydropyridazin-3-yl)methanol (3) 
 To a stirred solution of cycloadduct 2 (0.119 g; 0.461 mmol) in THF (2 mL) was added 
2ml of 2M NaOH. The mixture was left under reflux for 3h. After cooling down THF (2 ml) and a 
suspension of Amberlite (H+) in water was added to the reaction mixture. The mixture was 
swirled to promote contact and then immediately filtrated under vacuum. The solvent was 
evaporated. By adding acetone, water was co-evaporated in the rotary evaporator giving yellow 
oil (0.048 g; 91.0 %). [α]D
20 -20º (conc. 0.3%  in EtOH).  νmax (neat):  3422 (N-H), 1643 (C=C) cm
-1. 
δH (400 MHz, D2O) 6.01 (1H, ddd, J =2.4, 5.6, 10.4 Hz H-5), 5.79  (1H, ddd, J=2.0, 4.4, 10.4 Hz, H-
4), 3.65-3.57 (2H, m, H-3’), 3.54-3.48 (1H, m, H-3), 3.35 (1H, ddd, J=2.8, 5.2, 17.6 Hz H-6), 3.24 
(1H, ddd, J =2.6, 3.2, 17.2 Hz, H-6) ppm. δC (100.6 MHz, D2O) 127.4 (C-4 or C-5), 125.0  (C-5 or C-
4), 62.5 (C-3’), 54.8 (C-3), 44.2 (C-6) ppm. HRMS (ESI): calcd for C5H10N2O [M+H]
+ 114.0793; 
found: [M+H]+  115.0165. Anal. Calcd. for C5H10N2O: C, 52.63; H, 8.77; N, 24.56. Found: C, 52.67; 
H, 8.74; N, 24.51. 
Synthesis of tert-butyl (S)-3-(hydroxymethyl)-3,6-dihydropyridazine-1(2H)-carboxylate (N-
Boc-1-azafagomine)  (4) 
 To a stirred solution of compound 3 (0.044 g; 0.385 mmol) dissolved in ethanol (10 mL) 
was added solid NaOH (0.015 g; 0.385 mmol) and Boc2O (0.015 g; 0.385 mmol). The reaction 
mixture was left under magnetic stirring for 1 h at room temperature. Then the mixture was 
filtrated through a pad of celite and washed thoroughly with ethanol. The solution was 
concentrated to give a yellow solid. The yellow solid was dissolved in acetone, filtrated and the 
solution evaporated to give a yellow oil (0.077g; 93%) [α]D
20 + 67º (conc. 0.78 % in DCM).  
νmax(neat):  3269 (OH), 1694 (CO) cm
-1. δH (400 MHz, D2O) 5.96  (1H, br d, J =8.8, H-5), 5.90 (1H, 
bd, J =8.8, H-4), 4.09 (1H, bd, J=10.0 Hz, H-6), 3.96 (1H, bd, J=10.0 Hz, H-6), 3.68-3.56 (3H, m, H-
3, H-3’), 1.50 (9H, s, C(CH3)3) ppm. δC (100.6 MHz, D2O), 156.8 (C=O), 125.1, 125.0 (C-4 and C-5), 
82.7 (C), 61.8 (C-3’), 55.9 (C-3), 27.6 (C(CH3)3) ppm.  HRMS (ESI): calcd for C10H18N2O3 [M+H]
+ 
214.1317; found: [M-H]-  213.1591. Anal. Calcd. for C10H18N2O3: C, 56.07; H, 8.41; N, 13.08. 
Found: C, 56.11; H, 8.37; N, 13.05. 
Synthesis of tert-butyl (S)-7-oxo-4a,5-dihydro-7H-oxazolo[3,4-b]pyridazine-1(2H)-carboxylate 
(5) 
 To a stirred solution of compound 4 (0.114 g; 0.532 mmol) in dry DCM (10 ml) was added 
DIPEA (10 equiv.; 0.93 mL; 0.532 mmol) and triphosgene (0.5 equiv.; 0.077 g; 0.532 mmol). The 
mixture was left stirring under nitrogen for 5 min at room temperature. The solvent was 
removed, and the residue was purified by column chromatography (EtOAc : Pet. ether, 1:1) to 
give yellow oil (0.077g; 93%). [α]D
20 +30º (conc.0.4% DCM). νmax (neat): 1717 (C=O) cm
-1. δH (400 
MHz, DMSO) 5.89 (1H, dm, J 8.8) 5.86 (1H, (1H, ddd, J=8.4, 4.8, 2.0 Hz), 4.02 (2H, dd, J=4.8, 2.4 
Hz), 3.71 (1H, br s), 3.55 (1H, dd, J=11.2, 4.8 Hz), 3.46 (1H, J=11.2, 7.2 Hz) ppm. δC (100.6 MHz, 
DMSO-d6), 153.6 (CO), 152.6 (CO), 124.5-123.8  (C-H, Ar), 83.0, 81.6 (Cq), 60.4, 59.9 (CH2O), 
56.2, 55.6, 53.0 (CH), 43.8, 43.3 (CH2N), 27.9, 27.8, 27.7, 27.4 (CH3) ppm. HRMS (ESI): calcd for 
C11H16N2O4 [M+H]
+ 240.0793; found: [M+H]+  241.0165. Anal. Calcd. for C11H16N2O4: C, 55.00; H, 
6.66; N, 11.66. Found: C, 55.05; H, 6.63; N, 11.69. 
Synthesis of (3S,4R,4aR)-tert-butyl 3,4-dihydroxy-7-oxohexahydro-1H-oxazolo[3,4-
b]pyridazine-1-carboxylate (6) 
 Compound 5 (0.076; 0.316 mmol) was dissolved in a mixture of acetone (1.2 ml) and 
water (0.11 ml). To this solution N-methylmorpholine N-oxide (1.3 equiv., 0.048 g; 0.316 mmol) 
followed by a solution of OsO4 in water (4%; 34µl; 0.0053 mmol) were added. The reaction 
mixture was stirred for 1 day at room temperature. The solvents were evaporated until a 
residue, which was subsequently dissolved in ethyl acetate (20 ml) and washed with water (2 x 
15 ml). The organic fractions were combined, dried over MgSO4, filtrated, and the solution 
concentrated in the rotary evaporator to give an orange oil (0.078g; 90%). νmax (neat): 
1693(C=O) cm-1. NMR δH (400 MHz, CDCl3 ), 1.5 (9H, s, 3CH3), 3.42 (1H, m), 3.6 (2H, s, OH), 3.81 
(2H, d, J=2.4 Hz), 3.91 (2H, q, J=3.6 Hz), 4.34 (2H, t, J=2 Hz). δC (100.6 MHz, CDCl3), 28.07 (3CH3), 
29.6 (CH2N), 36.5 (CHN), 65.1(CH2O), 66.4 (CH-OH), 68.8 (CH-OH), 82.6 (C), 155.8 (CO), 162.6 
(CO) ppm. HRMS (EI): m/z calcd for  C11H18N2O6: 274.1165 [M + H]
+, found: [M + H]+ 274.0658. 
Anal. Calcd. for C11H18N2O6: C, 48.17; H, 6.56; N, 10.21. Found: C, 48.21; H, 6.59; N, 10.17. 
Synthesis of (3S,4R,4aR)-3,4-dihydroxytetrahydro-1H-oxazolo[3,4-b]pyridazin-7(2H)-one  (7) 
 To a solution of compound 6 (0.099 g, 0.361 mmol) in acetonitrile (3 ml) was added H2O 
(11 ml) and BiI3 (0.199 g, 0.726 mmol). The mixture was refluxed for 16 h (water bath 110 
0C). A 
column chromatography (DCM : EtOH, 7:3) was run giving a brown oil (0.069 g; 0.396 mmol, 55 
%). νmax (neat): 3404 (OH), 1745 (CO) cm
-1. (400 MHz, CD3OD) δH 4.57 (1H, br s), 4.44 (1H, dd, 
J=7.6, 8.8 Hz, H-3’), 4.26  (1H, dd, J=3.2, 8.8 Hz, H-3’), 3.86 (1H, ddd, J=3.6, 7,6, 10 Hz, H-5), 3.83-
3.81 (1H, m, H-3),  3.51 (1H, dd, J=2.6, 9.8 Hz, H-4 ), 2.97 (1H,  dd, J =2.8, 14.0 Hz,  H-6 ), 2.90 
(1H,  dd,  J= 1.2, 13.2 Hz, H-6) ppm. δC (100.6 MHz, CD3OD) 159.2 (CO), 70.7 (C-4), 67.0 (C-3), 
66.5 (CH2O), 55.0 (C-5), 52.5 (CH2-6) ppm. HRMS (ESI): m/z calcd for C6H10N2NaO4: 197.0538 [M 
+ Na]+, found: [M + Na]+ 197.0533. Anal. Calcd. for C6H10N2O4: C, 41.37; H, 5.74; N, 16.09. 
Found: C, 41.39; H, 5.71; N, 16.11. 
 
Biological activity 
 Antibacterial activity of compounds 3-7 and pristine antibiotics (cefotaxime and 
ceftriaxone) were tested by diffusion method on Staphylococcus aureus and Escherichia coli, as 
described by Mayrhofer [47]. Pristine antibiotics (cefotaxime and ceftriaxone) were taken in 
amount 25 μg (indicator disks were purchased by Research-and-Development Center of 
Pharmacotherapy, 192236 St. Petersburg). The synthesized substances were also taken in the 
amount equal to 25 μg. Escherichia coli was cultivated on Endo's medium and Staphylococcus 
aureus on Baird-Parker agar. Microbiological tests were performed on Petri dishes. Due to the 
fact that this method provides only quality data, microdilution method was also performed, as 
it is written by Jorgensen and Lee [48]. By this method, the MICs of the prepared compounds 3-
7 and usual antibiotics were identified and compared to each other. In order to perform the 
microdilution method, the stock solutions with different concentrations of the substances were 
prepared in distilled sterile water and were distributed in 96 multi-well plates. Each well was 
inoculated with 0.1 ml of microbial suspensions of 0.5 Mc Farland turbidity, prepared from 24h 
fresh culture. Sterility control wells (nutrient broth) and microbial growth controls (inoculated 




[46] K. Mori, Tetrahedron 1974, 30 (20), 3807-3810.  
[47] S. Mayrhofer, K.J.Domig, C.Mair, U.Zitz, G.Huys, W. Kneifel, Appl Environ Microbiol. 2008, 
74(12), 3745-3748.  


















C NMR (CDCl3) spectrum of compound 1 
 












C NMR (D2O) spectrum of compound 3 
 








C NMR (D2O) spectrum of compound 4 
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C NMR (DMSO-d6) spectrum of compound 5 
 
Figure S12. dept 135 NMR (DMSO-d6) spectrum of compound 5 
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C NMR (CDCl3) spectrum of compound 6 
 








C NMR (CD3OD) spectrum of compound 7 
 








































Mass spectra of compound 7 
 
 
